

# Project #355: Biosimilar Fill & Finish Unit



Contact: Mme. Hamdi Soukaina **Industrial Process Division** 

06 66 92 42 78 Shamdi@mcinet.gov.ma

# Project description



Manufacturing unit for biosimilars (Insulin, Erythropoietin, monoclonal antibodies...) which biotechnology-derived drugs based on a biological reference drug whose patent has fallen into the public domain

Main clients:

public health services and centers, private clinics

# **Branch**

Pharmaceutical Industry


### Sub-branch


Biosimilar

# **Financial indicators (indicative) Potential** ~50 - 100 Mns MAD investment **Potential** ~80 - 150 Mns MAD (of which 60% export) turnover **EBITDA**<sup>2</sup> ~15% - 25 % (in % of turnover) ~70 - 100 direct jobs **Jobs**

## **Key facts**

- Global market estimated at \$30 billion in 2020 and expected to grow at a rate of ~24% to reach \$100 billion by 2026
- Presence of only one operator in this field with a specialization on anticancer drugs





<sup>1.</sup> Product Complexity Index:the diversity and sophistication of the productive know-how required to produce a product. Products with high PCI value (the most complex products that only a few countries can produce) include electronics and chemicals. Products with a low PCI value (the least complex product that nearly all countries can produce) include raw materials and simple agricultural products.

<sup>2.</sup> Earnings before interest, taxes, depreciation and amortization

<sup>3.</sup> Source: Office des changes, TradeMap